Bulletin of Experimental Biology and Medicine

, Volume 158, Issue 5, pp 638–640 | Cite as

Serum Levels of Neurosteroids in Patients with Affective Disorders

  • L. A. Levchuk
  • N. M. Vyalova
  • S. A. Ivanova
  • G. G. Simutkin
  • E. V. Lebedeva
  • N. A. Bokhan
Article

According modern biological hypotheses of the pathogenesis of affective disorders, hypothalamic–pituitary–adrenal axis dysfunction play a special role in the pathogenesis of this condition. Our study shows that the range of neuroprotective neurosteroids is gender- and nosology-dependent. Patients with affective disorders have reduced levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate; the most pronounced defi ciency of neuroprotective neurosteroids is typical of patients with a single depressive episode. Reduced levels of neurosteroids producing an anabolic effect probably indicate depletion of adaptive capacities of the hypothalamic–pituitary–adrenal system in affective disorders.

Key Words

affective disorders dehydroepiandrosterone dehydroepiandrosterone sulfate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    N. A. Bokhan, S. A. Ivanova, and L. A. Levchuk, Serotonin System in the Modulation of Depressive and Aggressive Behavior [in Russian], Tomsk (2013).Google Scholar
  2. 2.
    N. P. Goncharov, G. V. Katsiya, and A. N. Nizhnik, Vestn. Ross. Akad. Med. Nauk, No. 8, 37–43 (2005).Google Scholar
  3. 3.
    S. A. Ivanova, L. A. Levchuk, E. V. Gutkevich, and V. Ya. Semke, Psikhiatriya, No. 3, 18–22 (2010).Google Scholar
  4. 4.
    Ya. A. Kochetkov, K. V. Bel’tikova, and L. N. Gorobets, Zh. Psikhiatr. Nevrol. im. S. S. Korsakova, 106, No. 10, 47–51 (2006).Google Scholar
  5. 5.
    V. N. Krasnov, Psikh. Rasstroystva Obshchey Meditsine, No. 2, 12–15 (2012).Google Scholar
  6. 6.
    E. V. Lebedeva, E. V. Gutkevich, S. A. Ivanova, et al., Sib. Vestn. Psikhiatr. Narkol., No. 6, 41–46 (2012).Google Scholar
  7. 7.
    V. A. Stoyak, E. V. Zhernova, N. A. Bokhan, and S. A. Ivanova, Sib. Vestn. Psikhiatr. Narkol., No. 4, 88–90 (2010).Google Scholar
  8. 8.
    V. A. Gavrilova, S. A. Ivanova, S. I. Gusev, et al., Bull. Exp. Biol. Med., 154, No. 1, 89–91 (2012).CrossRefPubMedGoogle Scholar
  9. 9.
    S. Haefner, T. C. Baghai, C. Schule, et al., Neuropsychobiology, 58, Nos. 3–4, 154–162 (2008).CrossRefPubMedGoogle Scholar
  10. 10.
    S. A. Ivanova, A. V. Semke, and O. Y. Fedorenko, Neurochem. J., 5, No. 4, 290–293 (2011).CrossRefGoogle Scholar
  11. 11.
    M. F. Juruena, A. J. Cleare, and C. M. Pariante, Rev. Bras. Psiquiatr., 26, No. 3, 189–201 (2004).CrossRefPubMedGoogle Scholar
  12. 12.
    H. Kurita, H. Maeshima, S. Kida, et al., J. Affect. Disord., 146, No. 2, 205–212 (2013).CrossRefPubMedGoogle Scholar
  13. 13.
    M. Schumacher, S. Weill-Engerer, P. Liere, et al., Prog. Neurobiol., 71, No. 1, 3–29 (2003).CrossRefPubMedGoogle Scholar
  14. 14.
    M. K. Taylor, Mil. Med., 178, No. 1, 100–106 (2013).CrossRefPubMedGoogle Scholar
  15. 15.
    S. A. Vreeburg, W. J. Hoogendijk, J. van Pelt, et al., Arch. Gen. Psychiatry, 66, No. 6, 617–626 (2009).CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • L. A. Levchuk
    • 1
  • N. M. Vyalova
    • 1
  • S. A. Ivanova
    • 1
  • G. G. Simutkin
    • 1
  • E. V. Lebedeva
    • 1
  • N. A. Bokhan
    • 1
    • 2
  1. 1.Mental Health Research InstituteSiberian Division of Russian Academy of Medical SciencesTomskRussia
  2. 2.National Research Tomsk State UniversityTomskRussia

Personalised recommendations